Complete remission in nonsyndromic childhood-onset epilepsy

Ann Neurol. 2011 Oct;70(4):566-73. doi: 10.1002/ana.22461. Epub 2011 Jun 27.

Abstract

Objective: Determine the probability of attaining complete remission in children with nonsyndromic epilepsy (NSE) over the course of ≥10 years from initial diagnosis; identify early predictors of complete remission; and assess the risk of relapse after achieving complete remission.

Methods: In a prospective community-based cohort, complete remission was defined as 5 years seizure-free and medication-free. Any subsequent seizure for any reason was a relapse. Univariate and bivariate analyses were conducted with standard methods including the Kaplan-Meier approach. Proportional hazards modeling was used for multivariable analysis.

Results: Of 613 cohort members, 347 had NSEs, of whom 294 (85%) were followed ≥10 years (maximum = 17.9). A total of 170 in 294 (58%) achieved complete remission, 10 of whom (6%) relapsed. Seizure outcome at 2 years (remission, pharmacoresistant, unclear) (p < 0.0001) and underlying cause (p < 0.0001) distinguished groups with complete remission ranging from ~20% to ~75%. Older age at onset was independently associated with a poorer chance of complete remission. Relapses occurred up to 7.5 years after attaining complete remission and were marginally associated with underlying cause (p = 0.06).

Interpretation: Complete remission occurs in over one-half of young people with NSE and generally persists. Meaningful but imperfect predication is possible based on underlying cause and early seizure control. The finding of age effects may play a role in meaningful identification of phenotypes, which could become fruitful targets for genetic and imaging investigations in these otherwise poorly differentiated epilepsies.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Age of Onset*
  • Anticonvulsants / therapeutic use
  • Child
  • Child, Preschool
  • Disease-Free Survival
  • Epilepsy / drug therapy
  • Epilepsy / physiopathology*
  • Female
  • Follow-Up Studies
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Prognosis
  • Prospective Studies
  • Remission Induction
  • Risk Factors
  • Secondary Prevention

Substances

  • Anticonvulsants